Effect of cilazapril on exercise tolerance in congestive heart failure

Pharmacology
C N CorderW Harwood

Abstract

Cilazapril (C), an angiotensin-converting enzyme inhibitor with effective antihypertensive efficacy, was examined for its ability to alter exercise tolerance testing (ETT) and respiratory oxygen uptake in 33 patients with congestive heart failure (CHF). C was administered in capsules daily to patients with New York Heart Association Class II or Class III CHF for 12 weeks, in parallel double-blind treatment groups of 0 mg (n = 8), 0.5 mg (n = 8), 1.0 mg (n = 9), and 2.5 mg (n = 8). The blood pressure (BP) was reduced by 2.5 mg C: systolic BP (SBP) from 126 to 114 mm Hg; diastolic BP from 76 to 69 mm Hg. The maximum heart rate (MHR) during ETT was increased by 2.5 mg C from 137 to 143 bpm, as was the double product (MHR x maximum SBP x 0.01) from 237 to 251. There was an insignificant change in duration of exercise (548-610 s), anaerobic threshold (AT), and maximum oxygen uptake (14.1-15.7 ml/kg/min). The results suggest a positive effect of 2.5 mg C on energy utilization in CHF patients.

Citations

Nov 1, 1996·Archives of Gerontology and Geriatrics·E FeracoA Madeo
Sep 10, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Antònia AgustíJoan-Ramon Laporte
Apr 12, 2016·Journal of Physical Therapy Science·Vinícius A CoelhoKaren B P Fernandes
Aug 9, 2006·Congestive Heart Failure·Sabu Thomas, Edward Geltman
Jun 29, 2018·The Cochrane Database of Systematic Reviews·Nicole MartinR Thomas Lumbers
May 23, 2021·The Cochrane Database of Systematic Reviews·Nicole MartinR Thomas Lumbers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.